$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000110465912075036 Filed on November 07, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q3
Revenue	$2.331B	$2.427B	$2.100B
YoY Change	7.32%	15.57%	1.2%
Cost Of Revenue	$388.0M	$376.0M	$379.0M
YoY Change	1.84%	-0.79%	-2.82%
Gross Profit	$1.943B	$1.845B	$1.721B
YoY Change	8.49%	7.21%	2.14%
Gross Profit Margin	83.35%	76.02%	81.95%
Selling, General & Admin	$1.091B	$1.050B	$1.002B
YoY Change	7.59%	4.79%	2.56%
% of Gross Profit	56.15%	56.91%	58.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$116.0M	$110.0M	$100.0M
YoY Change	16.0%	10.0%	-0.99%
% of Gross Profit	5.97%	5.96%	5.81%
Operating Expenses	$1.723B	$1.686B	$1.629B
YoY Change	7.49%	3.5%	2.91%
Operating Profit	$220.0M	$153.0M	$79.00M
YoY Change	17.02%	93.67%	-22.55%
Interest Expense	-$110.0M	$103.0M	$59.00M
YoY Change	10.0%	74.58%	-156.73%
% of Operating Profit	-50.0%	67.32%	74.68%
Other Income/Expense, Net
YoY Change
Pretax Income	$97.00M	$51.00M	$21.00M
YoY Change	-256.45%	142.86%	-133.87%
Income Tax	$35.00M	$18.00M	$4.000M
% Of Pretax Income	36.08%	35.29%	19.05%
Net Earnings	$49.00M	$32.00M	$15.00M
YoY Change	-170.0%	113.33%	-98.4%
Net Earnings / Revenue	2.1%	1.32%	0.71%
Basic Earnings Per Share		$0.38	$0.05
Diluted Earnings Per Share	$426.1K	$0.37	$0.05
COMMON SHARES
Basic Shares Outstanding	106.5M shares	104.2M shares	117.2M shares
Diluted Shares Outstanding		107.3M shares	120.9M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$364.0M	$83.00M	$185.0M
YoY Change	222.12%	-55.14%	-53.75%
Cash & Equivalents	$364.0M	$83.00M	$185.0M
Short-Term Investments
Other Short-Term Assets	$458.0M	$502.0M	$606.0M
YoY Change	21.16%	-17.16%	-18.33%
Inventory	$153.0M	$154.0M	$157.0M
Prepaid Expenses	$76.00M
Receivables	$1.345B	$1.338B	$1.221B
Other Receivables	$7.000M	$13.00M	$7.000M
Total Short-Term Assets	$2.681B	$2.484B	$2.176B
YoY Change	13.75%	14.15%	-10.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.293B	$4.173B	$4.201B
YoY Change	-1.31%	-0.67%	-0.9%
Goodwill	$916.0M	$771.0M
YoY Change	24.46%
Intangibles
YoY Change
Long-Term Investments	$22.00M	$126.0M	$159.0M
YoY Change	-4.35%	-20.75%	-9.66%
Other Assets	$342.0M	$338.0M	$533.0M
YoY Change	-8.56%	-36.59%	-16.19%
Total Long-Term Assets	$6.363B	$5.986B	$6.117B
YoY Change	4.23%	-2.14%	0.43%
TOTAL ASSETS
Total Short-Term Assets	$2.681B	$2.484B	$2.176B
Total Long-Term Assets	$6.363B	$5.986B	$6.117B
Total Assets	$9.044B	$8.470B	$8.293B
YoY Change	6.88%	2.13%	-2.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$722.0M	$629.0M	$629.0M
YoY Change	-5.0%	0.0%	4.66%
Accrued Expenses	$540.0M	$496.0M	$470.0M
YoY Change	-2.17%	5.53%	-6.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$94.00M	$243.0M	$129.0M
YoY Change	42.42%	88.37%	6350.0%
Total Short-Term Liabilities	$1.763B	$1.829B	$1.679B
YoY Change	-2.87%	8.93%	-1.0%
LONG-TERM LIABILITIES
Long-Term Debt	$5.158B	$4.508B	$3.966B
YoY Change	20.12%	13.67%	-2.24%
Other Long-Term Liabilities	$305.0M	$524.0M	$871.0M
YoY Change	-39.72%	-39.84%	-14.44%
Total Long-Term Liabilities	$305.0M	$524.0M	$4.837B
YoY Change	-39.72%	-89.17%	-4.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.763B	$1.829B	$1.679B
Total Long-Term Liabilities	$305.0M	$524.0M	$4.837B
Total Liabilities	$7.810B	$7.185B	$6.595B
YoY Change	12.31%	8.95%	-3.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.288B	-$1.337B
YoY Change	-10.56%
Common Stock	$7.000M	$7.000M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.979B	$1.879B
YoY Change	6.8%
Treasury Stock Shares	37.73M shares	34.32M shares
Shareholders Equity	$1.143B	$1.224B	$1.698B
YoY Change
Total Liabilities & Shareholders Equity	$9.044B	$8.470B	$8.293B
YoY Change	6.88%	2.13%	-2.84%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q3
OPERATING ACTIVITIES
Net Income	$49.00M	$32.00M	$15.00M
YoY Change	-170.0%	113.33%	-98.4%
Depreciation, Depletion And Amortization	$116.0M	$110.0M	$100.0M
YoY Change	16.0%	10.0%	-0.99%
Cash From Operating Activities	$256.0M	$136.0M	$148.0M
YoY Change	47.98%	-8.11%	15.63%
INVESTING ACTIVITIES
Capital Expenditures	-$148.0M	-$107.0M	-$97.00M
YoY Change	-14.45%	10.31%	-9.35%
Acquisitions
YoY Change
Other Investing Activities	-$168.0M	$9.000M	$4.000M
YoY Change	2700.0%	125.0%	-110.53%
Cash From Investing Activities	-$316.0M	-$98.00M	-$93.00M
YoY Change	76.54%	5.38%	-35.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$100.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	341.0M	-37.00M	-134.0M
YoY Change	-616.67%	-72.39%	-54.73%
NET CHANGE
Cash From Operating Activities	256.0M	136.0M	148.0M
Cash From Investing Activities	-316.0M	-98.00M	-93.00M
Cash From Financing Activities	341.0M	-37.00M	-134.0M
Net Change In Cash	281.0M	1.000M	-79.00M
YoY Change	-490.28%	-101.27%	-74.76%
FREE CASH FLOW
Cash From Operating Activities	$256.0M	$136.0M	$148.0M
Capital Expenditures	-$148.0M	-$107.0M	-$97.00M
Free Cash Flow	$404.0M	$243.0M	$245.0M
YoY Change	16.76%	-0.82%	4.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.35
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.36
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.25
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	58000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-30000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	1553000000	USD
	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	7373000000	USD
	thc	Number Of Free Standing And Provider Based Outpatient Centers Operated By Subsidiaries NumberOfFreeStandingAndProviderBasedOutpatientCentersOperatedBySubsidiaries	112	item
CY2012Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	243000000	USD
CY2011Q3	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	2289000000	USD
	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	7018000000	USD
CY2011Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	189000000	USD
CY2012Q3	us-gaap	Assets Assets	8470000000	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	2484000000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	298000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	536000000	USD
CY2011Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2100000000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	6482000000	USD
CY2011Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1002000000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3001000000	USD
CY2011Q3	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	379000000	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1167000000	USD
CY2011Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	527000000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1526000000	USD
CY2011Q3	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	0	USD
	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-50000000	USD
CY2011Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000000	USD
CY2011Q3	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	8000000	USD
	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	18000000	USD
CY2011Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5000000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-24000000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	79000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	498000000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	59000000	USD
	us-gaap	Interest Expense InterestExpense	275000000	USD
CY2011Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8470000000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	1224000000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	7185000000	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1829000000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113000000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1278000000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	161000000	USD
CY2011Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	418000000	USD
CY2011Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	2000000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	378000000	USD
CY2011Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	156000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	374000000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4350000000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	736000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	489000000	USD
CY2011Q4	us-gaap	Assets Assets	8462000000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	66000000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	760000000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	376000000	USD
CY2011Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	75000000	USD
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	112000000	USD
CY2011Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	64000000	USD
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	362000000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1815000000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4294000000	USD
CY2011Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	337000000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.06
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1492000000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	397000000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3386000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	360000000	USD
CY2011Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	2000000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	506000000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	6954000000	USD
CY2011Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	334000000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4427000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52000000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1440000000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1853000000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1423000000	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	69000000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8462000000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	3000000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	21000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	226000000	USD
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	73000000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	17000000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	153000000	USD
CY2011Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-2000000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-17000000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.15
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.15
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2012Q3	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2011Q4	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2012Q3	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Issued PreferredStockSevenPercentMandatoryConvertibleSharesIssued	46300	shares
CY2011Q4	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Issued PreferredStockSevenPercentMandatoryConvertibleSharesIssued	345000	shares
CY2012Q3	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2011Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1050000000	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	137867138	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	138739064	shares
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	34110674	shares
CY2012Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	34320438	shares
CY2012Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	405000000	USD
CY2012Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3444000000	USD
CY2012Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	402000000	USD
	dei	Entity Registrant Name EntityRegistrantName	TENET HEALTHCARE CORP
	dei	Entity Central Index Key EntityCentralIndexKey	0000070318
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106475474	shares
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	40000000	USD
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-24000000	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	7000000	USD
CY2011Q3	us-gaap	Profit Loss ProfitLoss	15000000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.07
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.11
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.07
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.03
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.08
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117188000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120204000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	120908000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124466000	shares
	us-gaap	Profit Loss ProfitLoss	160000000	USD
CY2011Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	18000000	USD
CY2011Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	8000000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	134000000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	8000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	128000000	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-2000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	6000000	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	32000000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1000000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	33000000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	51000000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	153000000	USD
CY2012Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2221000000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	6788000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	538000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	237000000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	147000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-68000000	USD
	us-gaap	Profit Loss ProfitLoss	79000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	92000000	USD
	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	100000000	USD
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	1000000	USD
CY2012Q3	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-1000000	USD
CY2012Q3	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	0	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.29
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.09
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.28
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.09
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104244000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107311000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106904000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103613000	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-21000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-346000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	337000000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	45000000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	76000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	292000000	USD
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	292000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3000000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	0	USD
CY2012Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	0	USD
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	0	USD
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	3000000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	3000000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	0	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	0	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	0	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	3000000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	0	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	0	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	32000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	82000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	95000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	8000000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	40000000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	3000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	102000000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	405000000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-17000000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	618000000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	44000000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-34000000	USD
	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	31000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Net Operating Revenues</font></i></b><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2"> Before Provision for Doubtful Accounts</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our</font><font style="FONT-SIZE: 10pt" size="2"> <i>Compact with Uninsured Patients </i>(“Compact”).</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The table below shows the sources of net operating revenues before provision for doubtful accounts:</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Three Months Ended<br /> September 30,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Nine Months Ended<br /> September 30,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">General Hospitals:</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Medicare </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">505</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">491</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,666</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,550</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Medicaid </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">176</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">174</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">587</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">609</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Managed care </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,348</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,269</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4,002</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,830</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Indemnity, self-pay and other </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">261</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">244</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">747</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">732</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Acute care hospitals — other revenue </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">27</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">45</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">78</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other:</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other operations </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">129</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">84</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">326</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">219</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 49%; PADDING-TOP: 0in" valign="bottom" width="49%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Net operating revenues before provision for doubtful accounts</font></b><font style="FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,427</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,289</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,373</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,018</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table>
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	8000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-220000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-220000000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83000000	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1338000000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-92000000	USD
CY2012Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4508000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	-255000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000000	USD
	thc	Number Of Hospitals Operated By Subsidiaries NumberOfHospitalsOperatedBySubsidiaries	49	item
	thc	Number Of Licensed Beds In Hospitals Operated By Subsidiaries NumberOfLicensedBedsInHospitalsOperatedBySubsidiaries	13261	item
CY2012Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	190000000	USD
CY2011Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	252000000	USD
CY2012Q3	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	71000000	USD
CY2011Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	92000000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	48000000	USD
CY2011	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	109000000	USD
CY2012Q3	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	43000000	USD
CY2011Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	104000000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	54000000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	983000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	849000000	USD
	us-gaap	Finite Lived Intangible Assets Future Amortization Expense FiniteLivedIntangibleAssetsFutureAmortizationExpense	578000000	USD
	us-gaap	Future Amortization Expense Remainder Of Fiscal Year FutureAmortizationExpenseRemainderOfFiscalYear	26000000	USD
	us-gaap	Future Amortization Expense Year Two FutureAmortizationExpenseYearTwo	89000000	USD
	us-gaap	Future Amortization Expense Year Three FutureAmortizationExpenseYearThree	82000000	USD
	us-gaap	Future Amortization Expense Year Four FutureAmortizationExpenseYearFour	72000000	USD
	us-gaap	Future Amortization Expense Year Five FutureAmortizationExpenseYearFive	67000000	USD
	us-gaap	Future Amortization Expense After Year Five FutureAmortizationExpenseAfterYearFive	242000000	USD
	thc	Cash And Cash Equivalents Maturity Period CashAndCashEquivalentsMaturityPeriod	3
CY2012Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	38000000	USD
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	150000000	USD
CY2011Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	53000000	USD
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	158000000	USD
CY2012Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	3000000	USD
CY2011Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-2000000	USD
CY2010Q4	us-gaap	Litigation Reserve LitigationReserve	5000000	USD
	thc	Litigation Settlements Net Of Insurance Recoveries LitigationSettlementsNetOfInsuranceRecoveries	10000000	USD
	thc	Number Of Lawsuits NumberOfLawsuits	2	lawsuit
	us-gaap	Insurance Recoveries InsuranceRecoveries	10000000	USD
CY2012Q3	us-gaap	Restructuring Reserve RestructuringReserve	12000000	USD
	us-gaap	Restructuring Reserve Period Expense RestructuringReservePeriodExpense	8000000	USD
	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	7000000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	0	USD
CY2011Q4	us-gaap	Restructuring Reserve RestructuringReserve	11000000	USD
CY2011Q3	us-gaap	Restructuring Reserve RestructuringReserve	15000000	USD
	us-gaap	Restructuring Reserve Period Expense RestructuringReservePeriodExpense	13000000	USD
	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	7000000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-1000000	USD
CY2010Q4	us-gaap	Restructuring Reserve RestructuringReserve	10000000	USD
	thc	Cash Payments To Be Applied Against Accruals Due Within One Year CashPaymentsToBeAppliedAgainstAccrualsDueWithinOneYear	2000000	USD
	thc	Cash Payments To Be Applied Against Accruals Due Thereafter CashPaymentsToBeAppliedAgainstAccrualsDueThereafter	10000000	USD
CY2012Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	85000000	USD
CY2012Q3	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	4751000000	USD
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	32000000	USD
CY2011Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	4360000000	USD
CY2012Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	7384874	shares
CY2012Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6911556	shares
CY2012Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1	4.5
CY2012Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	27.76
CY2012Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	28.11
CY2011Q2	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	400000000	USD
	thc	Stock Repurchase Program Expiration Date StockRepurchaseProgramExpirationDate	09-May-12
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	26000000	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	18942000	shares
CY2012Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1327000	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	20269000	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	19.75
CY2012Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	19.74
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	19.75
	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	26000000	USD
CY2012Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	11000000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-3000000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	9000000	USD
	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	2000000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-21000000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	30000000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1819000000	USD
CY2011Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1761000000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	8000000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	129000000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	196000000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6000000	USD
	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	81000000	USD
	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	92000000	USD
CY2012Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	110000000	USD
CY2011Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	66000000	USD
CY2010Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	30000000	USD
	us-gaap	Interest Expense InterestExpense	303000000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	800000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	314000000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	103000000	USD
CY2012Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2012Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2012Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10000000	USD
CY2012Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	15000000	USD
CY2012Q3	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3067000	shares
CY2012Q3	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.01
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	30000000	USD
	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3291000	shares
	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.04
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	129000000	USD
CY2011Q3	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2011Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3720000	shares
CY2011Q3	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
CY2012Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	38000000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	8000000	USD
	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	4262000	shares
	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.03
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	128000000	USD
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3711000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3711000	shares
CY2011Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4089000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4054000	shares
	us-gaap	Gain Loss On Investments GainLossOnInvestments	2000000	USD
CY2012Q3	thc	Preferred Stock And Other Securities Held By Captive Insurance Subsidiaries PreferredStockAndOtherSecuritiesHeldByCaptiveInsuranceSubsidiaries	1000000	USD
CY2012Q3	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.089	pure
CY2011Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.049	pure
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1337000000	USD
CY2012Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1879000000	USD
CY2012Q3	us-gaap	Minority Interest MinorityInterest	45000000	USD
CY2012Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	206000000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2000000	USD
CY2011	thc	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	thc	Number Of Hospitals Owned By Subsidiaries NumberOfHospitalsOwnedBySubsidiaries	49	item
	thc	Number Of Hospitals To Which Segment Of The Entity Provides Revenue Cycle Services NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices	400	item
CY2012Q3	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	269000000	USD
CY2012Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	10000000	USD
	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	294000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-324000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	196000000	USD
CY2012Q3	thc	Capital Expenditure CapitalExpenditure	108000000	USD
	thc	Capital Expenditure CapitalExpenditure	360000000	USD
CY2011Q3	thc	Capital Expenditure CapitalExpenditure	100000000	USD
	thc	Capital Expenditure CapitalExpenditure	298000000	USD
CY2011Q3	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	192000000	USD
	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	838000000	USD
	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	867000000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	12000000	USD
CY2011Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	8000000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	18000000	USD
CY2012Q3	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	51000000	USD
	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	237000000	USD
CY2011Q3	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	21000000	USD
	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	226000000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7000000	USD
CY2012Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	9000000	USD
CY2011Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	32000000	USD
	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	60000000	USD
	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	22000000	USD
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1000000	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.05
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.05
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	15000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	160000000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	134000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17000000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	23000000	USD
	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	32000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-96000000	USD
	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	27000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	324000000	USD
	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	4000000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	56000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1000000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	18000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6000000	USD
CY2012Q3	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-94000000	USD
CY2011Q3	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-68000000	USD
	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-274000000	USD
	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-192000000	USD
CY2012Q2	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Retired PreferredStockSevenPercentMandatoryConvertibleSharesRetired	298700	shares
CY2012Q3	thc	Debt Instrument Unamortized Discount Premium DebtInstrumentUnamortizedDiscountPremium	119000000	USD
CY2011Q4	thc	Debt Instrument Unamortized Discount Premium DebtInstrumentUnamortizedDiscountPremium	129000000	USD
CY2012Q2	thc	Preferred Stock Repurchased During Period Shares PreferredStockRepurchasedDuringPeriodShares	298700	shares
	thc	Repatriated Cash From Subsidiaries RepatriatedCashFromSubsidiaries	21000000	USD
	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	12000000	USD
	thc	Number Of Licensed Beds In Hospitals Operated By The Subsidiaries NumberOfLicensedBedsInHospitalsOperatedByTheSubsidiaries	13216	item
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	15000000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	578000000	USD
CY2011Q3	us-gaap	Long Lived Assets Held For Sale Impairment Charge LongLivedAssetsHeldForSaleImpairmentCharge	4000000	USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	thc	Number Of Free Standing And Provider Based Diagnostic Imaging Centers And Ambulatory Surgery Centers Operated By Subsidiaries Excluding Classified In Discontinued Operations NumberOfFreeStandingAndProviderBasedDiagnosticImagingCentersAndAmbulatorySurgeryCentersOperatedBySubsidiariesExcludingClassifiedInDiscontinuedOperations	112	item
CY2012Q3	us-gaap	Inventory Net InventoryNet	154000000	USD
CY2012Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	13000000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	394000000	USD
CY2012Q3	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	0	USD
CY2012Q3	us-gaap	Other Assets Current OtherAssetsCurrent	502000000	USD
CY2012Q3	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	126000000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	338000000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4173000000	USD
CY2012Q3	us-gaap	Goodwill Goodwill	771000000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	629000000	USD
CY2012Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	379000000	USD
CY2012Q3	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	72000000	USD
CY2012Q3	us-gaap	Interest Payable Current InterestPayableCurrent	110000000	USD
CY2012Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	7000000	USD
CY2012Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	389000000	USD
CY2012Q3	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	322000000	USD
CY2012Q3	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	2000000	USD
CY2012Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	524000000	USD
CY2012Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue	45000000	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4437000000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	585000000	USD
CY2012Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1050000000	USD
CY2012Q3	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	376000000	USD
CY2012Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	539000000	USD
CY2012Q3	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-13000000	USD
CY2012Q3	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	6000000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3166000000	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1164000000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1604000000	USD
	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-13000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000000	USD
CY2012Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	4000000	USD
CY2012Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	4000000	USD
CY2012Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1000000	USD
CY2012Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	USD
CY2011Q3	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	0	USD
CY2011Q3	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2011Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	7000000	USD
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-24000000	USD
	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	0	USD
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-24000000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	10000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-37000000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-9000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-24000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	24000000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7000000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	653000000	USD
	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	106000000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-23000000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20000000	USD
	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	56000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-19000000	USD
	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	358000000	USD
	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	2000000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	38000000	USD
	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	9000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2000000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	4000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1458000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	26000000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	13000000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	9000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	11000000	USD
CY2011Q3	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	192000000	USD
	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	838000000	USD
CY2012Q3	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	269000000	USD
	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	867000000	USD
CY2012Q4	thc	Stockholders Equity Reverse Stock Split Conversion Ratio StockholdersEquityReverseStockSplitConversionRatio	0.25	shares
	us-gaap	Interest Paid Net InterestPaidNet	-288000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-9000000	USD
CY2012Q3	thc	Common Stock Shares Authorized Before Reverse Stock Split CommonStockSharesAuthorizedBeforeReverseStockSplit	1050000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares

Files In Submission

Name	View Source	Status
0001104659-12-075036-index-headers.html	Edgar Link	pending
0001104659-12-075036-index.html	Edgar Link	pending
0001104659-12-075036.txt	Edgar Link	pending
0001104659-12-075036-xbrl.zip	Edgar Link	pending
a12-20742_110q.htm	Edgar Link	pending
a12-20742_1ex10dc.htm	Edgar Link	pending
a12-20742_1ex10dd.htm	Edgar Link	pending
a12-20742_1ex10de.htm	Edgar Link	pending
a12-20742_1ex10df.htm	Edgar Link	pending
a12-20742_1ex10dg.htm	Edgar Link	pending
a12-20742_1ex10dh.htm	Edgar Link	pending
a12-20742_1ex10di.htm	Edgar Link	pending
a12-20742_1ex10dj.htm	Edgar Link	pending
a12-20742_1ex10dk.htm	Edgar Link	pending
a12-20742_1ex31da.htm	Edgar Link	pending
a12-20742_1ex31db.htm	Edgar Link	pending
a12-20742_1ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g207421kg01i001.jpg	Edgar Link	pending
g207421ki01i001.jpg	Edgar Link	pending
g207421kk01i001.jpg	Edgar Link	pending
g207421km01i001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20120930.xml	Edgar Link	completed
thc-20120930.xsd	Edgar Link	pending
thc-20120930_cal.xml	Edgar Link	unprocessable
thc-20120930_def.xml	Edgar Link	unprocessable
thc-20120930_lab.xml	Edgar Link	unprocessable
thc-20120930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2012 Q4 Form 10-Q Financial Statement

#000110465912075036 Filed on November 07, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2012 Q4 Form 10-Q Financial Statement

#000110465912075036 Filed on November 07, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc